3:I[2885,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js"],"default"]
4:I[231,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js"],""]
5:I[9275,[],""]
7:I[1343,[],""]
8:I[8173,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","185","static/chunks/app/layout-24f8abeacb8025a3.js"],"Image"]
9:I[5864,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","185","static/chunks/app/layout-24f8abeacb8025a3.js"],"default"]
2:T579,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does LGP do?","acceptedAnswer":{"@type":"Answer","text":"Little Green Pharma (LGP) cultivates, manufactures, and globally distributes medicinal cannabis products, including oils and dried flower, to patients in Australia and various European markets like Germany and the UK."}},{"@type":"Question","name":"Is LGP a good investment?","acceptedAnswer":{"@type":"Answer","text":"LGP operates in a high-growth, yet speculative sector. While it offers significant upside potential from market expansion and product innovation, it also carries higher risks typical of micro-cap companies, including intense competition, regulatory challenges, and potential for ongoing losses requiring future capital raises. Investment suitability depends heavily on an individual's risk tolerance and belief in the long-term growth trajectory of the medicinal cannabis industry."}},{"@type":"Question","name":"What drives LGP's share price?","acceptedAnswer":{"@type":"Answer","text":"LGP's share price is primarily driven by news of international supply agreements, regulatory approvals for new products or markets, quarterly sales figures (especially international growth), capital raising activities, clinical trial results, and broader sentiment towards the medicinal cannabis sector both in Australia and globally."}}]}6:["ticker","LGP","d"]
0:["eimXLUBhqYQDb2tNGR8KG",[[["",{"children":["asx",{"children":[["ticker","LGP","d"],{"children":["__PAGE__?{\"ticker\":\"LGP\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","LGP","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Little Green Pharma Ltd"," (","LGP",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Little Green Pharma Ltd (ASX: LGP) is an Australian-based medicinal cannabis company focused on the cultivation, manufacturing, and global distribution of high-quality medicinal cannabis products. The company operates vertically integrated facilities and supplies a range of cannabis oils and dried flower products to patients in Australia and key international markets, primarily across Europe."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$37M"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","$L3",null,{"ticker":"LGP"}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","LGP operates in the burgeoning global medicinal cannabis market, positioning itself as a key Australian producer with a growing international footprint. Despite being a small-cap company (A$37M), it has established supply chains and regulatory approvals in several jurisdictions. Recent performance has likely seen revenue growth driven by increased patient access and expansion into new markets, though profitability remains a key challenge characteristic of many early-stage pharmaceutical companies in this sector.",{"children":"LGP operates in the burgeoning global medicinal cannabis market, positioning itself as a key Australian producer with a growing international footprint. Despite being a small-cap company (A$37M), it has established supply chains and regulatory approvals in several jurisdictions. Recent performance has likely seen revenue growth driven by increased patient access and expansion into new markets, though profitability remains a key challenge characteristic of many early-stage pharmaceutical companies in this sector."}],["$","p","The growth outlook for LGP is largely tied to increasing patient adoption of medicinal cannabis, further international market penetration, and product diversification. Upcoming catalysts could include new supply agreements in high-value European markets, additional product registrations with regulatory bodies like the TGA or EU equivalents, and potential M&A activity within a consolidating industry. The strategic direction appears focused on scaling production, expanding distribution networks, and enhancing product portfolios to capture a larger share of the global medicinal cannabis market.",{"children":"The growth outlook for LGP is largely tied to increasing patient adoption of medicinal cannabis, further international market penetration, and product diversification. Upcoming catalysts could include new supply agreements in high-value European markets, additional product registrations with regulatory bodies like the TGA or EU equivalents, and potential M&A activity within a consolidating industry. The strategic direction appears focused on scaling production, expanding distribution networks, and enhancing product portfolios to capture a larger share of the global medicinal cannabis market."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Significant growth potential from expanding medicinal cannabis markets in Europe, particularly Germany and the UK, where LGP has established operations.",{"children":["â€¢ ","Significant growth potential from expanding medicinal cannabis markets in Europe, particularly Germany and the UK, where LGP has established operations."]}],["$","li","Increasing patient and prescriber adoption in Australia and internationally, driven by growing acceptance and evolving regulatory frameworks.",{"children":["â€¢ ","Increasing patient and prescriber adoption in Australia and internationally, driven by growing acceptance and evolving regulatory frameworks."]}],["$","li","Diversification of product offerings and formulations, leading to broader market appeal and stronger competitive positioning.",{"children":["â€¢ ","Diversification of product offerings and formulations, leading to broader market appeal and stronger competitive positioning."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Intense competition from well-capitalised domestic and international medicinal cannabis producers, leading to potential pricing pressures and market share erosion.",{"children":["â€¢ ","Intense competition from well-capitalised domestic and international medicinal cannabis producers, leading to potential pricing pressures and market share erosion."]}],["$","li","Ongoing regulatory hurdles, delays in product approvals, and changes in government policy that could impact market access and operational costs.",{"children":["â€¢ ","Ongoing regulatory hurdles, delays in product approvals, and changes in government policy that could impact market access and operational costs."]}],["$","li","Continued operating losses and a reliance on future capital raises, which could dilute existing shareholder value given its small market capitalisation.",{"children":["â€¢ ","Continued operating losses and a reliance on future capital raises, which could dilute existing shareholder value given its small market capitalisation."]}]]}]]}]]}]]}],null,["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Investor Presentation - Proposed Merger"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"2 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"M&A"}]]}],""]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Quarterly Activities Report and Appendix 4C"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"29 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Quarterly Report"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"LGP's quarterly report details significant commitments test entity activities, including capital allocations for potential investors."}]]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Investor webinar invitation - proposed merger"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"28 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"M&A"}]]}],""]}],["$","div","3",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Transformational Merger of LGP and Cannatrek"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"13 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"M&A"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"LGP announces a transformative merger with cannatrek, creating an enhanced investment opportunity for stakeholders."}]]}],["$","div","4",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Proposed issue of securities - LGP"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"13 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does LGP do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does LGP do?"}],["$","p",null,{"className":"text-slate-400","children":"Little Green Pharma (LGP) cultivates, manufactures, and globally distributes medicinal cannabis products, including oils and dried flower, to patients in Australia and various European markets like Germany and the UK."}]]}],["$","div","Is LGP a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is LGP a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"LGP operates in a high-growth, yet speculative sector. While it offers significant upside potential from market expansion and product innovation, it also carries higher risks typical of micro-cap companies, including intense competition, regulatory challenges, and potential for ongoing losses requiring future capital raises. Investment suitability depends heavily on an individual's risk tolerance and belief in the long-term growth trajectory of the medicinal cannabis industry."}]]}],["$","div","What drives LGP's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives LGP's share price?"}],["$","p",null,{"className":"text-slate-400","children":"LGP's share price is primarily driven by news of international supply agreements, regulatory approvals for new products or markets, quarterly sales figures (especially international growth), capital raising activities, clinical trial results, and broader sentiment towards the medicinal cannabis sector both in Australia and globally."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","0.13"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-emerald-400","children":["0.0","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$37M"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"20/02/2020"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L4",null,{"href":"/asx/CSL","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","181.24"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-27.3","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$88.2B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/PNV","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.99"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-13.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$670M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/1AD","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.01"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-25.6","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$6","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"grid-glow min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L4",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L8",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L4","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L4","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L4","/sectors/materials",{"href":"/sectors/materials","className":"transition hover:text-white","children":"Sectors"}],["$","$L4","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L4","/compare/BHP-vs-RIO",{"href":"/compare/BHP-vs-RIO","className":"transition hover:text-white","children":"Compare"}],["$","$L4","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 md:flex","children":[["$","$L9",null,{}],["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden","children":[["$","div",null,{"className":"flex-1","children":["$","$L9",null,{}]}],["$","$L4",null,{"href":"/screener","className":"shrink-0 text-xs text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L4",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/0c5df3f3122977aa.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$La"]]]]]
a:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"LGP share price, analysis & company profile - Little Green Pharma Ltd | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest LGP share price overview, what Little Green Pharma Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/LGP/"}],["$","meta","5",{"property":"og:title","content":"LGP share price, analysis & company profile - Little Green Pharma Ltd"}],["$","meta","6",{"property":"og:description","content":"Latest LGP share price overview, what Little Green Pharma Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/LGP/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"LGP share price, analysis & company profile - Little Green Pharma Ltd"}],["$","meta","11",{"name":"twitter:description","content":"Latest LGP share price overview, what Little Green Pharma Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
